首页 > 最新文献

Journal of Community Genetics最新文献

英文 中文
Benefits and concerns of expanded carrier screening: what do pregnant Latina women in Texas think? 扩大携带者筛查的好处和担忧:德克萨斯州的拉丁裔孕妇怎么看?
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-12-01 Epub Date: 2023-10-14 DOI: 10.1007/s12687-023-00676-6
Embedzayi Madhiri, Haocen Wang, Melodie Tedross, Victoria Vidal, Christine Young, Denise Martinez, Wei-Ju Chen, Patricia Robbins-Furman, Robin Page, Nora Montalvo-Liendo, Lei-Shih Chen

The American College of Medical Genetics and Genomics (ACMG) recommends carrier screening for all pregnant women regardless of race or ethnicity. In recent years, the ACMG broadened the guidelines to include expanded carrier screening (ECS) which can screen for 112 conditions. This study seeks to explore the perceptions of pregnant Latina women about the benefits and concerns related to ECS use. Partnering with prenatal clinics in Texas, we conducted semi-structured qualitative interviews with 32 pregnant Latina women in their second or third trimester of pregnancy. NVivo 8 was used to conduct content analysis and emergent coding of the data. Participants reported the benefits of ECS as helping them prepare for the baby's arrival, informing them of the baby's risk for genetic conditions, ensuring the health of their baby, and preventing diseases before birth. The ECS-related concerns expressed by the participants included worries surrounding potential positive ECS results, insufficient knowledge about the genetic diseases screened for by ECS, the accuracy of the ECS, the potential harm ECS may cause the baby, and the affordability of ECS. After weighing both their perceived benefits and concerns, nearly all the participants believed that ECS should be offered to all pregnant women. This study contributes to an understudied research area in the genetic/genomic field. Our findings can help increase the awareness of obstetricians, genetic professionals, and other healthcare providers regarding pregnant Latina women's views on ECS and inform the design of culturally appropriate care as ECS is adopted into routine clinical practice.

美国医学遗传学和基因组学学院(ACMG)建议对所有孕妇进行携带者筛查,不分种族或民族。近年来,ACMG扩大了指南范围,包括可筛查112种疾病的扩大携带者筛查(ECS)。本研究旨在探讨拉丁美洲孕妇对ECS使用的益处和担忧的看法。我们与德克萨斯州的产前诊所合作,对32名妊娠中期或晚期的拉丁裔孕妇进行了半结构化的定性访谈。NVivo 8用于对数据进行内容分析和紧急编码。参与者报告了ECS的好处,帮助他们为婴儿的到来做准备,告知他们婴儿患遗传疾病的风险,确保婴儿的健康,并在出生前预防疾病。参与者表达的ECS相关担忧包括对潜在阳性ECS结果的担忧、对ECS筛查的遗传疾病、ECS的准确性、ECS可能对婴儿造成的潜在伤害以及ECS的可负担性了解不足。在权衡了他们所感知的好处和担忧后,几乎所有参与者都认为应该向所有孕妇提供ECS。这项研究有助于遗传学/基因组领域研究不足的领域。我们的研究结果有助于提高产科医生、遗传专业人员和其他医疗保健提供者对怀孕的拉丁裔妇女对ECS的看法的认识,并为ECS被纳入常规临床实践时的文化适宜护理设计提供信息。
{"title":"Benefits and concerns of expanded carrier screening: what do pregnant Latina women in Texas think?","authors":"Embedzayi Madhiri, Haocen Wang, Melodie Tedross, Victoria Vidal, Christine Young, Denise Martinez, Wei-Ju Chen, Patricia Robbins-Furman, Robin Page, Nora Montalvo-Liendo, Lei-Shih Chen","doi":"10.1007/s12687-023-00676-6","DOIUrl":"10.1007/s12687-023-00676-6","url":null,"abstract":"<p><p>The American College of Medical Genetics and Genomics (ACMG) recommends carrier screening for all pregnant women regardless of race or ethnicity. In recent years, the ACMG broadened the guidelines to include expanded carrier screening (ECS) which can screen for 112 conditions. This study seeks to explore the perceptions of pregnant Latina women about the benefits and concerns related to ECS use. Partnering with prenatal clinics in Texas, we conducted semi-structured qualitative interviews with 32 pregnant Latina women in their second or third trimester of pregnancy. NVivo 8 was used to conduct content analysis and emergent coding of the data. Participants reported the benefits of ECS as helping them prepare for the baby's arrival, informing them of the baby's risk for genetic conditions, ensuring the health of their baby, and preventing diseases before birth. The ECS-related concerns expressed by the participants included worries surrounding potential positive ECS results, insufficient knowledge about the genetic diseases screened for by ECS, the accuracy of the ECS, the potential harm ECS may cause the baby, and the affordability of ECS. After weighing both their perceived benefits and concerns, nearly all the participants believed that ECS should be offered to all pregnant women. This study contributes to an understudied research area in the genetic/genomic field. Our findings can help increase the awareness of obstetricians, genetic professionals, and other healthcare providers regarding pregnant Latina women's views on ECS and inform the design of culturally appropriate care as ECS is adopted into routine clinical practice.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"605-612"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41215906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prevalence of beta thalassemia carriers in India: a systematic review and meta-analysis. 印度β地中海贫血携带者的患病率:一项系统综述和荟萃分析。
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-12-01 Epub Date: 2023-10-20 DOI: 10.1007/s12687-023-00683-7
Dharmarajan Sumedha, Kar Anita

A large number of studies have reported that the prevalence of beta thalassemia carriers in India varies by ethnic groups. The objective of this study was to conduct a systematic review of the published studies and conduct a meta-analysis to determine the prevalence of beta thalassaemia carriers in India. A PubMed database search using keywords "beta thalassaemia AND India" identified 1088 articles of which 69 articles were included in the review. Studies using diagnostic tests and methods recommended by the International Council for Standardization in Haematology were used for calculation of pooled prevalence. Pooled prevalence was calculated using a random effects model using Review Manager version 5.3. Studies had screened five categories of populations, that is, the general population; tribal groups, communities not belonging to tribal groups, persons with anemia, and persons referred with a suspicion of hemoglobinopathy. This heterogeneity contributed to a high pooled prevalence of beta thalassemia carriers of 8.23% (95% CI 7.36-9.10). Sub-group analysis however yielded 3.74% (95% CI 2.52-4.97) pooled prevalence of beta thalassemia carriers in the general population. It was 4.6% (95% CI 3.2-6.2) among tribal groups. Quality of prevalence studies was limited by methodological issues including non-random sampling methods, heterogeneity of population types screened, and lack of use of recommended diagnostic cut-offs. Prevalence of beta thalassemia carriers was similar in tribal populations and the general population, indicating the need to further investigate the prevalence of beta thalassemia carriers in tribal groups.

大量研究报告称,印度β地中海贫血携带者的患病率因种族而异。本研究的目的是对已发表的研究进行系统回顾,并进行荟萃分析,以确定印度β地中海贫血携带者的患病率。PubMed数据库使用关键词“β地中海贫血与印度”进行搜索,确定了1088篇文章,其中69篇文章被纳入综述。使用国际血液学标准化委员会推荐的诊断测试和方法进行的研究用于计算合并患病率。使用Review Manager 5.3版的随机效应模型计算合并患病率。研究筛选了五类人群,即普通人群;部落团体、不属于部落团体的社区、贫血患者和疑似血红蛋白病患者。这种异质性导致β-地中海贫血携带者的合并患病率高达8.23%(95%CI 7.36-9.10)。然而,亚组分析得出,普通人群中β-地中海贫血症携带者的合并发病率为3.74%(95%CI 2.52-4.97)。在部落群体中为4.6%(95%CI 3.2-6.2)。流行率研究的质量受到方法学问题的限制,包括非随机抽样方法、筛查人群类型的异质性以及缺乏使用推荐的诊断截断值。β地中海贫血携带者在部落人群和普通人群中的患病率相似,这表明有必要进一步调查部落群体中β地中海贫血带菌者的患病率。
{"title":"Prevalence of beta thalassemia carriers in India: a systematic review and meta-analysis.","authors":"Dharmarajan Sumedha, Kar Anita","doi":"10.1007/s12687-023-00683-7","DOIUrl":"10.1007/s12687-023-00683-7","url":null,"abstract":"<p><p>A large number of studies have reported that the prevalence of beta thalassemia carriers in India varies by ethnic groups. The objective of this study was to conduct a systematic review of the published studies and conduct a meta-analysis to determine the prevalence of beta thalassaemia carriers in India. A PubMed database search using keywords \"beta thalassaemia AND India\" identified 1088 articles of which 69 articles were included in the review. Studies using diagnostic tests and methods recommended by the International Council for Standardization in Haematology were used for calculation of pooled prevalence. Pooled prevalence was calculated using a random effects model using Review Manager version 5.3. Studies had screened five categories of populations, that is, the general population; tribal groups, communities not belonging to tribal groups, persons with anemia, and persons referred with a suspicion of hemoglobinopathy. This heterogeneity contributed to a high pooled prevalence of beta thalassemia carriers of 8.23% (95% CI 7.36-9.10). Sub-group analysis however yielded 3.74% (95% CI 2.52-4.97) pooled prevalence of beta thalassemia carriers in the general population. It was 4.6% (95% CI 3.2-6.2) among tribal groups. Quality of prevalence studies was limited by methodological issues including non-random sampling methods, heterogeneity of population types screened, and lack of use of recommended diagnostic cut-offs. Prevalence of beta thalassemia carriers was similar in tribal populations and the general population, indicating the need to further investigate the prevalence of beta thalassemia carriers in tribal groups.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"527-541"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49683513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genetic risk prediction in Hispanics/Latinos: milestones, challenges, and social-ethical considerations. 西班牙裔/拉丁裔的遗传风险预测:里程碑、挑战和社会伦理考虑。
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-12-01 Epub Date: 2023-11-14 DOI: 10.1007/s12687-023-00686-4
Betzaida L Maldonado, Daniel G Piqué, Robert C Kaplan, Katrina G Claw, Christopher R Gignoux

Genome-wide association studies (GWAS) have allowed the identification of disease-associated variants, which can be leveraged to build polygenic scores (PGSs). Even though PGSs can be a valuable tool in personalized medicine, their predictive power is limited in populations of non-European ancestry, particularly in admixed populations. Recent efforts have focused on increasing racial and ethnic diversity in GWAS, thus, addressing some of the limitations of genetic risk prediction in these populations. Even with these efforts, few studies focus exclusively on Hispanics/Latinos. Additionally, Hispanic/Latino populations are often considered a single population despite varying admixture proportions between and within ethnic groups, diverse genetic heterogeneity, and demographic history. Combined with highly heterogeneous environmental and socioeconomic exposures, this diversity can reduce the transferability of genetic risk prediction models. Given the recent increase of genomic studies that include Hispanics/Latinos, we review the milestones and efforts that focus on genetic risk prediction, summarize the potential for improving PGS transferability, and highlight the challenges yet to be addressed. Additionally, we summarize social-ethical considerations and provide ideas to promote genetic risk prediction models that can be implemented equitably.

全基因组关联研究(GWAS)已经允许识别疾病相关变异,这可以用来建立多基因评分(pgs)。尽管pgs可以成为个性化医疗的宝贵工具,但它们在非欧洲血统人群中的预测能力有限,特别是在混合人群中。最近的努力集中在增加GWAS的种族和民族多样性上,从而解决了这些人群遗传风险预测的一些局限性。即使有了这些努力,很少有研究只关注西班牙裔/拉丁裔。此外,西班牙裔/拉丁裔人口通常被认为是一个单一的人口,尽管不同种族群体之间和内部的混合比例不同,遗传异质性不同,人口历史也不同。与高度异质性的环境和社会经济暴露相结合,这种多样性会降低遗传风险预测模型的可转移性。鉴于最近包括西班牙裔/拉丁裔在内的基因组研究的增加,我们回顾了遗传风险预测的里程碑和努力,总结了提高PGS可转移性的潜力,并强调了尚未解决的挑战。此外,我们总结了社会伦理方面的考虑,并提出了促进遗传风险预测模型公平实施的思路。
{"title":"Genetic risk prediction in Hispanics/Latinos: milestones, challenges, and social-ethical considerations.","authors":"Betzaida L Maldonado, Daniel G Piqué, Robert C Kaplan, Katrina G Claw, Christopher R Gignoux","doi":"10.1007/s12687-023-00686-4","DOIUrl":"10.1007/s12687-023-00686-4","url":null,"abstract":"<p><p>Genome-wide association studies (GWAS) have allowed the identification of disease-associated variants, which can be leveraged to build polygenic scores (PGSs). Even though PGSs can be a valuable tool in personalized medicine, their predictive power is limited in populations of non-European ancestry, particularly in admixed populations. Recent efforts have focused on increasing racial and ethnic diversity in GWAS, thus, addressing some of the limitations of genetic risk prediction in these populations. Even with these efforts, few studies focus exclusively on Hispanics/Latinos. Additionally, Hispanic/Latino populations are often considered a single population despite varying admixture proportions between and within ethnic groups, diverse genetic heterogeneity, and demographic history. Combined with highly heterogeneous environmental and socioeconomic exposures, this diversity can reduce the transferability of genetic risk prediction models. Given the recent increase of genomic studies that include Hispanics/Latinos, we review the milestones and efforts that focus on genetic risk prediction, summarize the potential for improving PGS transferability, and highlight the challenges yet to be addressed. Additionally, we summarize social-ethical considerations and provide ideas to promote genetic risk prediction models that can be implemented equitably.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"543-553"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92156884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The CPT1A Arctic variant: perspectives of community members and providers in two Alaska tribal health settings. CPT1A北极变体:阿拉斯加两个部落卫生环境中社区成员和提供者的观点。
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-12-01 Epub Date: 2023-10-17 DOI: 10.1007/s12687-023-00684-6
Julie A Beans, Susan Brown Trinidad, Aliassa L Shane, Kyle A Wark, Jaedon P Avey, Charlene Apok, Tiffany Guinn, Samantha Kleindienst Robler, Matthew Hirschfeld, David M Koeller, Denise A Dillard

Newborn screening in Alaska includes screening for carnitine palmitoyltransferase 1A (CPT1A) deficiency. The CPT1A Arctic variant is a variant highly prevalent among Indigenous peoples in the Arctic. In this study, we sought to elicit Alaska Native (AN) community member and AN-serving healthcare providers' knowledge and perspectives on the CPT1A Arctic variant. Focus groups with community members and healthcare providers were held in two regions of Alaska between October 2018 and January 2019. Thematic analysis was used to identify recurring constructs. Knowledge and understanding about the CPT1A Arctic variant and its health impact varied, and participants were interested in learning more about it. Additional education for healthcare professionals was recommended to improve providers' ability to communicate with family caregivers about the Arctic variant. Engagement with AN community members identified opportunities to improve educational outreach via multiple modalities for providers and caregivers on the Arctic variant, which could help to increase culturally relevant guidance and avoid stigmatization, undue worry, and unnecessary intervention. Education and guidance on the care of infants and children homozygous for the CPT1A Arctic variant could improve care and reduce negative psychosocial effects.

阿拉斯加的新生儿筛查包括肉碱棕榈酰转移酶1A(CPT1A)缺乏症的筛查。CPT1A北极变体是一种在北极土著人民中高度流行的变体。在这项研究中,我们试图了解阿拉斯加原住民(AN)社区成员和AN服务的医疗保健提供者对CPT1A北极变种的知识和观点。2018年10月至2019年1月,在阿拉斯加的两个地区举行了由社区成员和医疗保健提供者组成的焦点小组。主题分析用于识别重复出现的结构。对CPT1A北极变种及其健康影响的知识和理解各不相同,参与者有兴趣了解更多关于它的信息。建议对医疗保健专业人员进行额外教育,以提高提供者与家庭护理人员就北极变种进行沟通的能力。与AN社区成员的接触确定了通过北极变体的提供者和照顾者的多种方式来改善教育外展的机会,这有助于增加与文化相关的指导,避免污名化、过度担忧和不必要的干预。对CPT1A北极变体纯合子婴儿和儿童的护理进行教育和指导可以改善护理并减少负面的心理社会影响。
{"title":"The CPT1A Arctic variant: perspectives of community members and providers in two Alaska tribal health settings.","authors":"Julie A Beans, Susan Brown Trinidad, Aliassa L Shane, Kyle A Wark, Jaedon P Avey, Charlene Apok, Tiffany Guinn, Samantha Kleindienst Robler, Matthew Hirschfeld, David M Koeller, Denise A Dillard","doi":"10.1007/s12687-023-00684-6","DOIUrl":"10.1007/s12687-023-00684-6","url":null,"abstract":"<p><p>Newborn screening in Alaska includes screening for carnitine palmitoyltransferase 1A (CPT1A) deficiency. The CPT1A Arctic variant is a variant highly prevalent among Indigenous peoples in the Arctic. In this study, we sought to elicit Alaska Native (AN) community member and AN-serving healthcare providers' knowledge and perspectives on the CPT1A Arctic variant. Focus groups with community members and healthcare providers were held in two regions of Alaska between October 2018 and January 2019. Thematic analysis was used to identify recurring constructs. Knowledge and understanding about the CPT1A Arctic variant and its health impact varied, and participants were interested in learning more about it. Additional education for healthcare professionals was recommended to improve providers' ability to communicate with family caregivers about the Arctic variant. Engagement with AN community members identified opportunities to improve educational outreach via multiple modalities for providers and caregivers on the Arctic variant, which could help to increase culturally relevant guidance and avoid stigmatization, undue worry, and unnecessary intervention. Education and guidance on the care of infants and children homozygous for the CPT1A Arctic variant could improve care and reduce negative psychosocial effects.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"613-620"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725401/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41239717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Psychosocial impacts of caring for a child with a genetic disorder in Accra, Ghana. 加纳阿克拉照顾遗传病患儿的社会心理影响。
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-12-01 Epub Date: 2023-08-15 DOI: 10.1007/s12687-023-00662-y
Paul Opoku, Annabella Osei-Tutu, Mabel Oti-Boadi

Caregivers caring for a child with a genetic condition may experience psychosocial distress, which may be compounded by the context in which the caring takes place. Few studies have examined psychosocial distress and support among caregivers caring for a child with a genetic disorder in low-middle-income countries such as Ghana. The purpose of the current study was to investigate the psychosocial impacts of caring for a child with a genetic disorder in an urban setting in Ghana's capital, Accra. We conducted individual interviews among 17 caregivers who were taking care of children with various genetic disorders including, albinism, Edward's syndrome, osteogenesis imperfecta, sickle cell disease, and spondyloepiphyseal dysplasia congenita. Thematic analysis of the data revealed three main themes on the psychosocial impacts, including: (1) self-blame, guilt, and shame; (2) sleep and mood disturbances; and (3) discrimination and stigmatization. We observed three themes about support: (1) psychological support; (2) family and community support; and (3) institutional support. Participants reported limited support from professionals such as psychologists. Discussion focuses on the supportive care needs of caregivers and implications for genetic counselling awareness, advocacy, and training.

照顾遗传病患儿的照顾者可能会经历心理社会困扰,而这种困扰可能会因照顾环境而加剧。在加纳等中低收入国家,很少有研究对照顾遗传病患儿的照顾者的社会心理压力和支持情况进行调查。本研究旨在调查在加纳首都阿克拉的城市环境中,照顾遗传病患儿对社会心理的影响。我们对 17 名照顾患有各种遗传疾病(包括白化病、爱德华综合征、成骨不全症、镰状细胞病和先天性脊柱软骨发育不良)儿童的照顾者进行了个别访谈。对数据进行的主题分析揭示了社会心理影响的三大主题,包括:(1) 自责、内疚和羞愧;(2) 睡眠和情绪障碍;(3) 歧视和侮辱。我们观察到有关支持的三个主题:(1) 心理支持;(2) 家庭和社区支持;(3) 机构支持。参与者报告称,来自心理学家等专业人士的支持有限。讨论的重点是护理人员的支持性护理需求以及对遗传咨询意识、宣传和培训的影响。
{"title":"Psychosocial impacts of caring for a child with a genetic disorder in Accra, Ghana.","authors":"Paul Opoku, Annabella Osei-Tutu, Mabel Oti-Boadi","doi":"10.1007/s12687-023-00662-y","DOIUrl":"10.1007/s12687-023-00662-y","url":null,"abstract":"<p><p>Caregivers caring for a child with a genetic condition may experience psychosocial distress, which may be compounded by the context in which the caring takes place. Few studies have examined psychosocial distress and support among caregivers caring for a child with a genetic disorder in low-middle-income countries such as Ghana. The purpose of the current study was to investigate the psychosocial impacts of caring for a child with a genetic disorder in an urban setting in Ghana's capital, Accra. We conducted individual interviews among 17 caregivers who were taking care of children with various genetic disorders including, albinism, Edward's syndrome, osteogenesis imperfecta, sickle cell disease, and spondyloepiphyseal dysplasia congenita. Thematic analysis of the data revealed three main themes on the psychosocial impacts, including: (1) self-blame, guilt, and shame; (2) sleep and mood disturbances; and (3) discrimination and stigmatization. We observed three themes about support: (1) psychological support; (2) family and community support; and (3) institutional support. Participants reported limited support from professionals such as psychologists. Discussion focuses on the supportive care needs of caregivers and implications for genetic counselling awareness, advocacy, and training.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"565-574"},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10725383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10001109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical utility of polygenic risk scores: a critical 2023 appraisal. 多基因风险评分的临床实用性:2023年的关键评估。
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-10-01 Epub Date: 2023-05-03 DOI: 10.1007/s12687-023-00645-z
Sebastian Koch, Jörg Schmidtke, Michael Krawczak, Amke Caliebe

Since their first appearance in the context of schizophrenia and bipolar disorder in 2009, polygenic risk scores (PRSs) have been described for a large number of common complex diseases. However, the clinical utility of PRSs in disease risk assessment or therapeutic decision making is likely limited because PRSs usually only account for the heritable component of a trait and ignore the etiological role of environment and lifestyle. We surveyed the current state of PRSs for various diseases, including breast cancer, diabetes, prostate cancer, coronary artery disease, and Parkinson disease, with an extra focus upon the potential improvement of clinical scores by their combination with PRSs. We observed that the diagnostic and prognostic performance of PRSs alone is consistently low, as expected. Moreover, combining a PRS with a clinical score at best led to moderate improvement of the power of either risk marker. Despite the large number of PRSs reported in the scientific literature, prospective studies of their clinical utility, particularly of the PRS-associated improvement of standard screening or therapeutic procedures, are still rare. In conclusion, the benefit to individual patients or the health care system in general of PRS-based extensions of existing diagnostic or treatment regimens is still difficult to judge.

自2009年首次出现在精神分裂症和双相情感障碍的背景下以来,多基因风险评分(PRS)已被描述用于大量常见的复杂疾病。然而,PRS在疾病风险评估或治疗决策中的临床应用可能是有限的,因为PRS通常只考虑一种特征的可遗传成分,而忽略了环境和生活方式的病因作用。我们调查了各种疾病的PRS的现状,包括乳腺癌症、糖尿病、癌症、冠状动脉疾病和帕金森病,并特别关注它们与PRS结合对临床评分的潜在改善。我们观察到,正如预期的那样,单独使用PRS的诊断和预后表现一直很低。此外,将PRS与临床评分相结合,充其量可以适度改善任一风险标志物的功效。尽管科学文献中报道了大量PRS,但对其临床效用的前瞻性研究,特别是与PRS相关的标准筛查或治疗程序的改进,仍然很少。总之,基于PRS的现有诊断或治疗方案的扩展对个体患者或整个医疗保健系统的益处仍然难以判断。
{"title":"Clinical utility of polygenic risk scores: a critical 2023 appraisal.","authors":"Sebastian Koch,&nbsp;Jörg Schmidtke,&nbsp;Michael Krawczak,&nbsp;Amke Caliebe","doi":"10.1007/s12687-023-00645-z","DOIUrl":"10.1007/s12687-023-00645-z","url":null,"abstract":"<p><p>Since their first appearance in the context of schizophrenia and bipolar disorder in 2009, polygenic risk scores (PRSs) have been described for a large number of common complex diseases. However, the clinical utility of PRSs in disease risk assessment or therapeutic decision making is likely limited because PRSs usually only account for the heritable component of a trait and ignore the etiological role of environment and lifestyle. We surveyed the current state of PRSs for various diseases, including breast cancer, diabetes, prostate cancer, coronary artery disease, and Parkinson disease, with an extra focus upon the potential improvement of clinical scores by their combination with PRSs. We observed that the diagnostic and prognostic performance of PRSs alone is consistently low, as expected. Moreover, combining a PRS with a clinical score at best led to moderate improvement of the power of either risk marker. Despite the large number of PRSs reported in the scientific literature, prospective studies of their clinical utility, particularly of the PRS-associated improvement of standard screening or therapeutic procedures, are still rare. In conclusion, the benefit to individual patients or the health care system in general of PRS-based extensions of existing diagnostic or treatment regimens is still difficult to judge.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"471-487"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9400035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores. 多因素疾病遗传风险预测的伦理、法律和社会影响:一项叙述性综述,确定了对多基因评分的解释和使用的担忧。
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-10-01 Epub Date: 2022-12-19 DOI: 10.1007/s12687-022-00625-9
Carolyn Riley Chapman

Advances in genomics have enabled the development of polygenic scores (PGS), sometimes called polygenic risk scores, in the context of multifactorial diseases and disorders such as cancer, cardiovascular disease, and schizophrenia. PGS estimate an individual's genetic predisposition, as compared to other members of a population, for conditions which are influenced by both genetic and environmental factors. There is significant interest in using genetic risk prediction afforded through PGS in public health, clinical care, and research settings, yet many acknowledge the need to thoughtfully consider and address ethical, legal, and social implications (ELSI). To contribute to this effort, this paper reports on a narrative review of the literature, with the aim of identifying and categorizing ELSI relating to genetic risk prediction in the context of multifactorial disease, which have been raised by scholars in the field. Ninety-two articles, spanning from 1977 to 2021, met the inclusion criteria for this study. Identified ELSI included potential benefits, challenges and risks that focused on concerns about interpretation and use, and ethical obligations to maximize benefits, minimize risks, promote justice, and support autonomy. This research will support geneticists, clinicians, genetic counselors, patients, patient advocates, and policymakers in recognizing and addressing ethical concerns associated with PGS; it will also guide future empirical and normative research.

基因组学的进步使得多基因评分(PGS),有时被称为多基因风险评分,在癌症、心血管疾病和精神分裂症等多因素疾病和病症的背景下得以发展。PGS估计个体与群体中其他成员相比,在受遗传和环境因素影响的情况下的遗传倾向。人们对在公共卫生、临床护理和研究环境中使用PGS提供的遗传风险预测非常感兴趣,但许多人承认需要深思熟虑地考虑和解决伦理、法律和社会影响(ELSI)。为了促进这项工作,本文对该领域学者提出的文献进行了叙述性综述,目的是识别和分类与多因素疾病背景下的遗传风险预测相关的ELSI。从1977年到2021年的92篇文章符合本研究的纳入标准。已确定的ELSI包括潜在利益、挑战和风险,重点关注解释和使用方面的问题,以及最大限度地提高利益、最大限度地减少风险、促进正义和支持自主性的道德义务。这项研究将支持遗传学家、临床医生、遗传顾问、患者、患者权益倡导者和政策制定者认识和解决与PGS相关的伦理问题;它还将指导未来的实证和规范研究。
{"title":"Ethical, legal, and social implications of genetic risk prediction for multifactorial disease: a narrative review identifying concerns about interpretation and use of polygenic scores.","authors":"Carolyn Riley Chapman","doi":"10.1007/s12687-022-00625-9","DOIUrl":"10.1007/s12687-022-00625-9","url":null,"abstract":"<p><p>Advances in genomics have enabled the development of polygenic scores (PGS), sometimes called polygenic risk scores, in the context of multifactorial diseases and disorders such as cancer, cardiovascular disease, and schizophrenia. PGS estimate an individual's genetic predisposition, as compared to other members of a population, for conditions which are influenced by both genetic and environmental factors. There is significant interest in using genetic risk prediction afforded through PGS in public health, clinical care, and research settings, yet many acknowledge the need to thoughtfully consider and address ethical, legal, and social implications (ELSI). To contribute to this effort, this paper reports on a narrative review of the literature, with the aim of identifying and categorizing ELSI relating to genetic risk prediction in the context of multifactorial disease, which have been raised by scholars in the field. Ninety-two articles, spanning from 1977 to 2021, met the inclusion criteria for this study. Identified ELSI included potential benefits, challenges and risks that focused on concerns about interpretation and use, and ethical obligations to maximize benefits, minimize risks, promote justice, and support autonomy. This research will support geneticists, clinicians, genetic counselors, patients, patient advocates, and policymakers in recognizing and addressing ethical concerns associated with PGS; it will also guide future empirical and normative research.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"441-452"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576696/pdf/12687_2022_Article_625.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10380742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
What makes a good life: using theatrical performance to enhance communication about polygenic risk scores research in patient and public involvement. 美好生活的意义:利用戏剧表演加强患者和公众参与中多基因风险评分研究的沟通。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2023-10-01 Epub Date: 2023-02-10 DOI: 10.1007/s12687-023-00635-1
Amy M Mason, Ifunanya Obi, Olamide Ayodele, Samuel A Lambert, Sarah Fahle

The aim of this patient and public involvement and engagement (PPIE) work was to explore improvised theatre as a tool for facilitating bi-directional dialogue between researchers and patients/members of the public on the topic of polygenic risk scores (PRS) use within primary or secondary care. PRS are a tool to quantify genetic risk for a heritable disease or trait and may be used to predict future health outcomes. In the United Kingdom (UK), they are often cited as a next-in-line public health tool to be implemented, and their use in consumer genetic testing as well as patient-facing settings is increasing. Despite their potential clinical utility, broader themes about how they might influence an individual's perception of disease risk and decision-making are an active area of research; however, this has mostly been in the setting of return of results to patients. We worked with a youth theatre group and patients involved in a PPIE group to develop two short plays about public perceptions of genetic risk information that could be captured by PRS. These plays were shared in a workshop with patients/members of the public to facilitate discussions about PRS and their perceived benefits, concerns and emotional reactions. Discussions with both performers and patients/public raised three key questions: (1) can the data be trusted?; (2) does knowing genetic risk actually help the patient?; and (3) what makes a life worthwhile? Creating and watching fictional narratives helped all participants explore the potential use of PRS in a clinical setting, informing future research considerations and improving communication between the researchers and lay members of the PPIE group.

这项患者和公众参与和参与(PPIE)工作的目的是探索简易剧场,将其作为一种工具,促进研究人员和患者/公众之间就多基因风险评分(PRS)在初级或二级护理中的使用进行双向对话。PRS是一种量化可遗传疾病或特征遗传风险的工具,可用于预测未来的健康结果。在英国,它们经常被认为是下一个需要实施的公共卫生工具,并且在消费者基因检测和面向患者的环境中的使用正在增加。尽管它们具有潜在的临床效用,但关于它们如何影响个人对疾病风险的感知和决策的更广泛主题是一个活跃的研究领域;然而,这主要是在将结果返回给患者的情况下发生的。我们与一个青年剧团和PPIE小组的患者合作,制作了两部短剧,讲述公众对PRS可以捕捉到的遗传风险信息的看法。这些剧本在研讨会上与患者/公众分享,以促进关于PRS及其感知的益处、担忧和情绪反应的讨论。与表演者和患者/公众的讨论提出了三个关键问题:(1)数据是否可信?;(2) 知道基因风险真的对患者有帮助吗?;以及(3)是什么让生命有价值?创造和观看虚构的叙事有助于所有参与者探索PRS在临床环境中的潜在用途,为未来的研究考虑提供信息,并改善研究人员与PPIE小组非专业成员之间的沟通。
{"title":"What makes a good life: using theatrical performance to enhance communication about polygenic risk scores research in patient and public involvement.","authors":"Amy M Mason, Ifunanya Obi, Olamide Ayodele, Samuel A Lambert, Sarah Fahle","doi":"10.1007/s12687-023-00635-1","DOIUrl":"10.1007/s12687-023-00635-1","url":null,"abstract":"<p><p>The aim of this patient and public involvement and engagement (PPIE) work was to explore improvised theatre as a tool for facilitating bi-directional dialogue between researchers and patients/members of the public on the topic of polygenic risk scores (PRS) use within primary or secondary care. PRS are a tool to quantify genetic risk for a heritable disease or trait and may be used to predict future health outcomes. In the United Kingdom (UK), they are often cited as a next-in-line public health tool to be implemented, and their use in consumer genetic testing as well as patient-facing settings is increasing. Despite their potential clinical utility, broader themes about how they might influence an individual's perception of disease risk and decision-making are an active area of research; however, this has mostly been in the setting of return of results to patients. We worked with a youth theatre group and patients involved in a PPIE group to develop two short plays about public perceptions of genetic risk information that could be captured by PRS. These plays were shared in a workshop with patients/members of the public to facilitate discussions about PRS and their perceived benefits, concerns and emotional reactions. Discussions with both performers and patients/public raised three key questions: (1) can the data be trusted?; (2) does knowing genetic risk actually help the patient?; and (3) what makes a life worthwhile? Creating and watching fictional narratives helped all participants explore the potential use of PRS in a clinical setting, informing future research considerations and improving communication between the researchers and lay members of the PPIE group.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"453-458"},"PeriodicalIF":1.5,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10742606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are we nearly there yet? Starts and stops on the road to use of polygenic scores. 我们快到了吗?在道路上开始和停止使用多基因评分。
IF 1.9 Q4 GENETICS & HEREDITY Pub Date : 2023-10-01 DOI: 10.1007/s12687-023-00672-w
Sowmiya Moorthie, Daphne Oluwasen Martschenko, Segun Fatumo
{"title":"Are we nearly there yet? Starts and stops on the road to use of polygenic scores.","authors":"Sowmiya Moorthie,&nbsp;Daphne Oluwasen Martschenko,&nbsp;Segun Fatumo","doi":"10.1007/s12687-023-00672-w","DOIUrl":"10.1007/s12687-023-00672-w","url":null,"abstract":"","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"439-440"},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576688/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of polygenic risk scores in breast cancer risk perception and decision-making. 多基因风险评分在乳腺癌症风险认知和决策中的作用。
IF 1.5 Q4 GENETICS & HEREDITY Pub Date : 2023-10-01 Epub Date: 2023-06-13 DOI: 10.1007/s12687-023-00655-x
Leslie Riddle, Galen Joseph, Mikaella Caruncho, Barbara Ann Koenig, Jennifer Elyse James

Polygenic risk scores (PRS) have the potential to improve the accuracy of clinical risk assessments, yet questions about their clinical validity and readiness for clinical implementation persist. Understanding how individuals integrate and act on the information provided by PRS is critical for their effective integration into routine clinical care, yet few studies have examined how individuals respond to the receipt of polygenic risk information. We conducted an embedded Ethical, Legal, and Social Implications (ELSI) study to examine if and how unaffected participants in a US population breast cancer screening trial understood and utilized PRS, as part of a multifactorial risk score combining traditional risk factors with a genetic risk assessment, to make screening and risk-reduction decisions. Semi-structured qualitative interviews were conducted with 24 trial participants who were designated at elevated risk for breast cancer due to their combined risk score. Interviews were analyzed using a grounded theory approach. Participants understood PRS conceptually and accepted it as one of many risk factors to consider, yet the value and meaning they ascribed to this risk estimate varied. Most participants reported financial and insurance barriers to enhanced screening with MRI and were not interested in taking risk-reducing medications. These findings contribute to our understanding of how PRS may be best translated from research to clinical care. Furthermore, they illuminate ethical concerns about identifying risk and making recommendations based on polygenic risk in a population screening context where many may have trouble accessing appropriate care.

多基因风险评分(PRS)有可能提高临床风险评估的准确性,但关于其临床有效性和临床实施准备情况的问题仍然存在。了解个体如何整合PRS提供的信息并对其采取行动,对于其有效整合到常规临床护理中至关重要,但很少有研究研究个体对收到多基因风险信息的反应。我们进行了一项嵌入式伦理、法律和社会影响(ELSI)研究,以检查美国人群癌症筛查试验中未受影响的参与者是否以及如何理解和利用PRS,作为将传统风险因素与遗传风险评估相结合的多因素风险评分的一部分,来做出筛查和风险降低决策。对24名试验参与者进行了半结构化定性访谈,这些参与者因其综合风险评分而被指定为癌症风险较高的人群。访谈采用扎根理论方法进行分析。参与者从概念上理解PRS,并将其视为需要考虑的众多风险因素之一,但他们对该风险估计的价值和含义各不相同。大多数参与者报告说,MRI强化筛查存在财务和保险障碍,对服用降低风险的药物不感兴趣。这些发现有助于我们理解PRS如何最好地从研究转化为临床护理。此外,它们阐明了在人群筛查背景下识别风险并根据多基因风险提出建议的伦理问题,在这种情况下,许多人可能难以获得适当的护理。
{"title":"The role of polygenic risk scores in breast cancer risk perception and decision-making.","authors":"Leslie Riddle, Galen Joseph, Mikaella Caruncho, Barbara Ann Koenig, Jennifer Elyse James","doi":"10.1007/s12687-023-00655-x","DOIUrl":"10.1007/s12687-023-00655-x","url":null,"abstract":"<p><p>Polygenic risk scores (PRS) have the potential to improve the accuracy of clinical risk assessments, yet questions about their clinical validity and readiness for clinical implementation persist. Understanding how individuals integrate and act on the information provided by PRS is critical for their effective integration into routine clinical care, yet few studies have examined how individuals respond to the receipt of polygenic risk information. We conducted an embedded Ethical, Legal, and Social Implications (ELSI) study to examine if and how unaffected participants in a US population breast cancer screening trial understood and utilized PRS, as part of a multifactorial risk score combining traditional risk factors with a genetic risk assessment, to make screening and risk-reduction decisions. Semi-structured qualitative interviews were conducted with 24 trial participants who were designated at elevated risk for breast cancer due to their combined risk score. Interviews were analyzed using a grounded theory approach. Participants understood PRS conceptually and accepted it as one of many risk factors to consider, yet the value and meaning they ascribed to this risk estimate varied. Most participants reported financial and insurance barriers to enhanced screening with MRI and were not interested in taking risk-reducing medications. These findings contribute to our understanding of how PRS may be best translated from research to clinical care. Furthermore, they illuminate ethical concerns about identifying risk and making recommendations based on polygenic risk in a population screening context where many may have trouble accessing appropriate care.</p>","PeriodicalId":46965,"journal":{"name":"Journal of Community Genetics","volume":" ","pages":"489-501"},"PeriodicalIF":1.5,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9630345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Community Genetics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1